Top

Published in:

01-06-2019 | Acute Coronary Syndrome | CE - Research Letter to the Editor

Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease

Authors: Felice Gragnano, Fabio Fimiani, Marco Di Maio, Arturo Cesaro, Giuseppe Limongelli, Davide Cattano, Paolo Calabrò

Published in: Internal and Emergency Medicine | Issue 4/2019

Excerpt

Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease, acting by either accelerating atherosclerosis progression or inducing a prothrombotic/antifibrinolytic systemic milieu [1‐3]. Several studies support the relevant role of Lp(a) in the occurrence of coronary events, especially in patients with premature coronary artery disease (CAD) [4‐6]. However, the association of elevated Lp(a) levels with the risk of recurrent cardiovascular events in patients with a prior coronary event optimally treated with statins remains controversial [7]. We sought to assess the impact of Lp(a) levels on the recurrence of cardiovascular events in patients with premature CAD treated with percutaneous coronary intervention (PCI). …

Ferretti G, Bacchetti T, Johnston TP et al (2018) Lipoprotein(a): a missing culprit in the management of athero-thrombosis? J Cell Physiol 233:2966–2981. https://doi.org/10.1002/jcp.26050 CrossRefPubMed

Gragnano F, Calabrò P (2018) Role of dual lipid-lowering therapy in coronary atherosclerosis regression: evidence from recent studies. Atherosclerosis 269:219–228. https://doi.org/10.1016/j.atherosclerosis.2018.01.012 CrossRefPubMed

Fogacci F, Cicero AF, D’Addato S, D’Agostini L, Rosticci M, Giovannini M, Bertagnin E, Borghi C, Brisighella Heart Study Group (2017) Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study. Eur J Intern Med 37:49–55. https://doi.org/10.1016/j.ejim.2016.08.018 CrossRefPubMed

Scanu AM (1992) Lipoprotein(a): a genetic risk factor for premature coronary heart disease. JAMA, J Am Med Assoc 267:3326–3329. https://doi.org/10.1001/jama.267.24.3326 CrossRef

Rallidis LS, Pavlakis G, Foscolou A et al (2018) High levels of lipoprotein (a) and premature acute coronary syndrome. Atherosclerosis 269:29–34. https://doi.org/10.1016/j.atherosclerosis.2017.12.011 CrossRefPubMed

Marcucci R, Brunelli T, Fedi S et al (2005) Relevance of post-methionine homocysteine and lipoprotein (a) in evaluating the cardiovascular risk in young CAD patients. Eur J Clin Invest 35:1–7. https://doi.org/10.1111/j.1365-2362.2005.01439.x CrossRefPubMed

Schwartz GG, Ballantyne CM, Barter PJ et al (2018) Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-outcomes randomized clinical trial. JAMA Cardiol 3:164–168. https://doi.org/10.1001/jamacardio.2017.3833 CrossRefPubMed

Milionis HJ, Filippatos TD, Loukas T et al (2006) Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. Atherosclerosis 187:170–176. https://doi.org/10.1016/j.atherosclerosis.2005.08.036 CrossRefPubMed

Tsimikas S (2017) A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 69:692–711. https://doi.org/10.1016/j.jacc.2016.11.042 CrossRef

10.

Chiarugi L, Prisco D, Antonucci E et al (2001) Lipoprotein (a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty. Atherosclerosis 154:129–135CrossRefPubMed

11.

Catapano AL, Graham I, De Backer G et al (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37:2999–3058l. https://doi.org/10.1093/eurheartj/ehw272 CrossRef

12.

Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S (2019) Relationship between low-density lipoprotein cholesterol and lipoprotein(a) lowering in response to PCSK9 inhibition with evolocumab. J Am Heart Assoc 8:e010932. https://doi.org/10.1161/JAHA.118.010932 CrossRefPubMedPubMedCentral

13.

Gragnano F, Natale F, Concilio C et al (2018) Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience. J Cardiovasc Med 19:75–77. https://doi.org/10.2459/JCM.0000000000000611 CrossRef

14.

Schettler VJJ, Neumann CL, Peter C et al (2017) Current insights into the German lipoprotein apheresis registry (GLAR)—almost 5 years on. Atheroscler Suppl 30:50–55. https://doi.org/10.1016/j.atherosclerosissup.2017.05.006 CrossRefPubMed

15.

Viney NJ, van Capelleveen JC, Geary RS et al (2016) Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388:2239–2253. https://doi.org/10.1016/S0140-6736(16)31009-1 CrossRef

Title: Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease
Authors: Felice Gragnano
Fabio Fimiani
Marco Di Maio
Arturo Cesaro
Giuseppe Limongelli
Davide Cattano
Paolo Calabrò
Publication date: 01-06-2019
Publisher: Springer International Publishing
Keywords: Acute Coronary Syndrome
Arterial Diseases
Published in: Internal and Emergency Medicine / Issue 4/2019
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-019-02082-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2019

Could hypoglycemia and hypoalbuminemia allow the identification of septic patients at high mortality risk in addition of clinical scores?

Prevalence of antiphospholipid antibodies among patients with chronic thromboembolic pulmonary hypertension

Retroperitoneal dedifferentiated liposarcoma

Leptin: a marker of renal injury

Symptom expression in advanced cancer patients admitted to hospice or home care with and without delirium

Intranasal sufentanil given in the emergency department triage zone for severe acute traumatic pain: a randomized double-blind controlled trail—reply

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page